News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
The Swedish biotech company Cellevate has raised €3.2 million in a seed round to fuel the commercialization of its nanofiber-based viral vector manufacturing technology in November.
The new company focuses on producing components needed to manufacture RNA-based therapies for which there is increasing demand.
With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion program in the company’s history.
Alison has more than 35 years of broad experience delivering clinical trials to sponsors with a patient centric mindset.
MinervaX and Wacker Biotech announced yesterday that they have entered into a manufacturing agreement for MinervaX’s prophylactic vaccine against Group B Streptococcus infections.